Role of Estrogens in Dementing Illnesses: Hypotheses on the Biological Rationale

  • Stefano Govoni
  • Daniela Solano
  • Bruno S. Solerte
  • Antonio Guaita
  • Marco Racchi
Part of the Medical Science Symposia Series book series (MSSS, volume 13)


Epidemiological data [1] indicate that postmenopausal estrogen replacement therapy (ERT) may be associated with a reduced risk of Alzheimer’s disease (AD) and ERT may also improve the cognitive performance of AD affected women. Moreover epidemiological data [2] suggest a sex difference in the prevalence of AD. The decline in sex steroid levels during aging has been widely studied; the receptor distribution in brain mirrors the distribution of the neuropathological markers of AD, therefore it is possible that estrogen levels decay in postmenopause contributes to the exacerbation of molecular events taking place with aging, thus leading to the development of AD.


Amyloid Precursor Protein Estrogen Replacement Therapy Nerve Growth Factor Receptor DEMENTING Illness Amyloid Precursor Protein Metabolism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tang M, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 1996;348:429–32.PubMedCrossRefGoogle Scholar
  2. 2.
    Fratiglioni L, Viitanen M, Vonstrauss E, et al. Very old women at highest risk of dementia and AD — incidence data from the Kungsholmen project, Stockholm, Neurology 1997;48: 132–38.PubMedGoogle Scholar
  3. 3.
    Gasparini L, Racchi M, Binetti G, et al. Peripheral markers in testing pathophysiological hypotheses and diagnosing AD. FASEB J 1998;12:17–34.PubMedGoogle Scholar
  4. 4.
    Govoni S, Trabucchi M, Racchi M, Biological basis for the pharmacological modulation of APP metabolism. In: Brunello N, et al. (editors). Mental disorders in the elderly: New therapeutic approaches. Berlin: Karger, 1998: 84–90.Google Scholar
  5. 5.
    Sohrabji F, Miranda RC, Toran-Allerand CD. Estrogen differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. J Neurosci 1994;14:459–71.PubMedGoogle Scholar
  6. 6.
    Toran-Allerand CD, Miranda RC, Bentham WDL, et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci USA 1992;89:4668–72.PubMedCrossRefGoogle Scholar
  7. 7.
    Keller JN, Germeyer A, Begley JG, Mattson MP. 17β-estradiol attenuates oxidative impairment of synaptic Na+K+-ATPase activity, glucose transport, and glutamate transport induced by amyloid-peptide and iron. J Neurosci Res 1997;50:522–30.PubMedCrossRefGoogle Scholar
  8. 8.
    Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE. Estrogen regulates metabolism of APP. J Biol Chem 1994;269:13065–68.PubMedGoogle Scholar
  9. 9.
    Xu H, Gouras GK, Greenfield JP, et al. Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides. Nature Med 1998;4:447–51.PubMedCrossRefGoogle Scholar
  10. 10.
    Ianna P, Racchi M, Cattaneo E, et al. Estrogen effect on brain biology and cognition. In: Paoletti R, et al (editors). Women’s health and menopause. Dordrecht: Kluwer Academic Publisher, 1997: 191–98.Google Scholar
  11. 11.
    Gasparini L, Racchi M, Benussi L, et al. Effect of energy shortage and oxidative stress on APP metabolism in cos cells. Neurosci Lett 1997;23:113–17.CrossRefGoogle Scholar
  12. 12.
    Srivastava RAK, Bhasin N, Srivastava N. ApoE gene expression in various tissues of mouse and regulation by estrogen. Biochem Mol Biol Intern 1996;38:91–101.Google Scholar
  13. 13.
    Bellosta S, Nathan BP, Orth M, et al. Stable expression and secretion of apo E3 and E4 in mouse neuroblastoma cells. J Biol Chem 1995;270:27063–61.PubMedCrossRefGoogle Scholar
  14. 14.
    Brandi L, Becherini L, Gennari L, et al. Association of the estrogen receptor gene polymorphisms with sporadic AD. Neurobiol Aging 1998;19(Supp.1):124.Google Scholar
  15. 15.
    Gennari L, Becherini L, Masi L, et al. Vitamin D and estrogen receptor allelic variants in Italian postmenopausal women: Evidence of multiple gene contribution to bone mineral density. J Clin Endocrinol Metab 1998;83:938–44.CrossRefGoogle Scholar
  16. 16.
    Johansson C, Skogg L. A population based study on the association between dementia and hip fractures in 85 year olds. Aging Clin & Expt Res 1996;8:189–96.Google Scholar
  17. 17.
    Meier-Ruge W, Bertoni-Freddari C, Iwangoff P. Changes in brain glucose metabolism as a key to the pathogenesis of AD. Gerontology 1994;40:246–52.PubMedCrossRefGoogle Scholar
  18. 18.
    Manning CA, Ragozzino ME, Gold PE. Glucose enhancement of memory in patients with probable SDAT. Neurobiol Aging 1993;14:523–28.PubMedCrossRefGoogle Scholar
  19. 19.
    Solerte SB, Cerutti N, Fioravanti M, et al. Alterations of 24-h serum insulin profile in patients with SDAT: Potential link with the cognitive derangement. Aging Clin Exp Res 1997;9(Suppl.4):85.Google Scholar

Copyright information

© Kluwer Academic Publishers and Fondazione Giovanni Lorenzini 1999

Authors and Affiliations

  • Stefano Govoni
  • Daniela Solano
  • Bruno S. Solerte
  • Antonio Guaita
  • Marco Racchi

There are no affiliations available

Personalised recommendations